Here is a recent email sent by Genelex’s CEO, Howard Coleman to people with an interest in personalized medicine: It’s time to express your opinion on whether warfarin (Coumadin) DNA testing should be paid for by insurance. The Center for Medicare and Medicaid Services (CMS) has initiated a study of this topic and is accepting [...]
Filed under: Cytochrome P450, Personalized Medicine, Pharmacogenetics | Tagged: cytochrome 2C9, medicaid, medicare, Personalized Medicine, Pharmacogenetics, VKORC1, warfarin | 2 Comments »
